Denali Therapeutics is a American biotechnology company headquartered in South San Francisco, California, founded in 2013 as a spin-off from Biogen. The company is focused exclusively on developing therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and Parkinson's disease. Denali's proprietary platform technologies include the Transport Vehicle (TV) platform for enhanced brain delivery of biologics[1].
Denali was founded in 2013 by scientists from Biogen, including Dr. Ryan Watts and Dr. Alex Schuth, with a mission to develop breakthrough therapies for neurodegenerative diseases. The company went public in 2017[1:1].
Key milestones:
Denali has one of the most robust neurodegenerative disease pipelines in biotech, with programs across Alzheimer's disease, Parkinson's disease, ALS, and Frontotemporal Dementia.
DNL310 is an enzyme replacement therapy for mucopolysaccharidosis II (Hunter syndrome) using Denali's Transport Vehicle platform. Not directly AD/PD but demonstrates TV platform capability[1:3].
DNL151 is a small molecule LRRK2 kinase inhibitor being developed for Parkinson's disease. LRRK2 mutations are the most common genetic cause of familial PD. The program has completed Phase 1 and advanced to Phase 2[2].
DNL126 is an antibody designed to activate TREM2, a receptor on microglia that plays a critical role in the brain's immune response to amyloid plaques. TREM2 variants are significant genetic risk factors for Alzheimer's disease[3].
DNL593 is an ATV (ApoE Transfer Vehicle):PGRN (progranulin) fusion protein being developed for ALS and Frontotemporal Dementia. Progranulin deficiency is linked to these conditions[4].
Denali's proprietary Transport Vehicle platform enables enhanced delivery of therapeutics across the blood-brain barrier (BBB). The TV platform uses a receptor-mediated transcytosis approach to transport large molecules into the brain[1:4].
Denali partnered with Biogen in 2020 to develop therapeutics using the Transport Vehicle platform for neurological diseases. This partnership has provided significant funding and expertise[1:5].
Denali has partnered with Sanofi for certain programs in neurodegeneration[1:6].
Denali Therapeutics Official Website](/therapeutics)
Denali Pipeline](/therapeutics)
LRRK2 Pathway - LRRK2 kinase dysfunction in PD
TREM2 Signaling - Microglial activation target
Lysosomal Dysfunction - GBA-linked pathways
Tau Pathology - Tau targeting programs
Parkinson's Disease Clinical Trials - Current PD trials](/clinical-trials)
Alzheimer's Disease Clinical Trials - AD trials
Denali Therapeutics Inc. Corporate Overview. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Denali Therapeutics. DNL151 LRRK2 Program. 2024. ↩︎
Schwartzentruber G, et al. TREM2 and Alzheimer's Disease. Nature. 2011. ↩︎
Baker M, et al. Progranulin Mutations in Frontotemporal Dementia. Nature. 2006. ↩︎